Thursday, 06 August 2020


AbbVie, Genmab enter $4B cancer immunotherapy partnership

11 June 2020 | News

The collaboration injects $750 million upfront payment to Genmab to focus on bispecific antibodies and drug discovery research with commercial responsibilities at Japan and US

image courtesy: freepik

image courtesy: freepik

US-based AbbVie and Genmab announced on 10 June 2020 that they had formed the partnership that will focus on bispecific antibodies, a kind of immunotherapy, across haematological and solid tumour cancers. They will additionally partner in discovery research. 

Under the terms of the deal, AbbVie will pay Genmab $750 million upfront, along with up to $3.15 billion in milestone payments.

The partnership focuses on three bispecific antibody development programs:

  • epcoritamab, which targets the cell-surface antigen CD20 as well as CD3 on T cells
  • DuoHexaBody-CD37
  • DuoBody-CD3x5T4

The companies will split commercial responsibilities in the U.S. and Japan for epcoritamab, while AbbVie will be responsible for further globalization, with Genmab booking net U.S. and Japanese sales and receiving tiered royalties for other territories. The companies will then share global development and commercialization for the other two antibodies while sharing commercialization responsibilities for the U.S. and Japan. For the discovery research partnership, Genmab will conduct Phase I studies, while AbbVie will have opt-in rights.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls